237 related articles for article (PubMed ID: 9336655)
1. Biologic characteristics of breast cancer detected by mammography and by palpation in a screening program: a pilot study.
Tweedie E; Tonkin K; Kerkvliet N; Doig GS; Sparrow RK; O'Malley FP
Clin Invest Med; 1997 Oct; 20(5):300-7. PubMed ID: 9336655
[TBL] [Abstract][Full Text] [Related]
2. Axillary node dissection in patients with breast cancer diagnosed through the Ontario Breast Screening Program: a need for minimally invasive techniques.
Singhal H; O'Malley FP; Tweedie E; Stitt L; Tonkin KS
Can J Surg; 1997 Oct; 40(5):377-82. PubMed ID: 9336528
[TBL] [Abstract][Full Text] [Related]
3. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas.
Tuck AB; O'Malley FP; Singhal H; Tonkin KS; Harris JF; Bautista D; Chambers AF
Arch Pathol Lab Med; 1997 Jun; 121(6):578-84. PubMed ID: 9199622
[TBL] [Abstract][Full Text] [Related]
5. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
6. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
7. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy.
Meijnen P; Oldenburg HS; Loo CE; Nieweg OE; Peterse JL; Rutgers EJ
Br J Surg; 2007 Aug; 94(8):952-6. PubMed ID: 17440955
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
9. Occult breast lesion localization plus sentinel node biopsy (SNOLL): experience with 959 patients at the European Institute of Oncology.
Monti S; Galimberti V; Trifiro G; De Cicco C; Peradze N; Brenelli F; Fernandez-Rodriguez J; Rotmensz N; Latronico A; Berrettini A; Mauri M; Machado L; Luini A; Paganelli G
Ann Surg Oncol; 2007 Oct; 14(10):2928-31. PubMed ID: 17674108
[TBL] [Abstract][Full Text] [Related]
10. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
12. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project.
Ng EH; Ng FC; Tan PH; Low SC; Chiang G; Tan KP; Seow A; Emmanuel S; Tan CH; Ho GH; Ng LT; Wilde CC
Cancer; 1998 Apr; 82(8):1521-8. PubMed ID: 9554530
[TBL] [Abstract][Full Text] [Related]
13. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
14. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
[TBL] [Abstract][Full Text] [Related]
16. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
18. Breast carcinoma in women 35 years and younger: a pathological study.
Fernandopulle SM; Cher-Siangang P; Tan PH
Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of p53 expression in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty KK
Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057
[TBL] [Abstract][Full Text] [Related]
20. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
